BlackDoctor1h
When Cystic Fibrosis Hits the Lungs, HIT BACK
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Healio5d
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Hosted on MSN1mon
Next-in-Class Once-Daily Pill Approved for Cystic Fibrosis
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
Medscape6d
Novel Once-Daily Cystic Fibrosis Treatment Matches Standard Therapy in Phase 3 Trials
A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...
Morningstar1mon
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK™ is approved for patients 6 years and older with at ...
Cystic Fibrosis Foundation7d
How I Discovered I Had Cystic Fibrosis
I spent my childhood and young adulthood being told I was “too young and healthy” to be dealing with the health issues I experienced. But as an adult, I was determined to find answers, and eventually, ...
Healthline1mon
What Medical Procedures Are Used for Cystic Fibrosis (CF)?
Cystic fibrosis (CF) is a genetic condition that leads ... from 119 endoscopic sinus surgeries performed on 88 people over 6 years. The researchers focused on changes in sinus scores and lung ...
Hosted on MSN1mon
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...
Nasdaq1mon
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have ... severe hepatic impairment (Child-Pugh Class C). ALYFTREK is not recommended in ...